Retrospective analysis reveals tumor diameter slope changes in IDH-mutated glioma patients undergoing vorasidenib treatment, suggesting individual response patterns.
The INDIGO trial demonstrated improved progression-free survival under vorasidenib in IDH-mutated grade 2 glioma patients. However, the pattern of vorasidenib effects remains unknown. We thus performed a retrospective analysis of tumor kinetics in eight patients enrolled in the INDIGO trial. Tumor diameters (computed from FLAIR volumetry) and their slopes were individually estimated, before and under vorasidenib. Three patients showed no change in slope. Three patients exhibited a marked slope decrease, and two demonstrated slope inversion. Tumor diameter slopes allows individual assessment of radiological response, providing clinically relevant insights that cannot be captured by the cohort-level analysis performed in the INDIGO trial.
No takes yet. Share an insight, caveat, or question.
Emmanuel Mandonnet (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: